ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Currently, tyrosine kinase inhibitors are the preferredfirst-line therapy for CML and based on IRIS trialdata a 3-log reduction in BCR-ABL transcript levels after12 months correlates with progression-free survival [1,2,3,4,5,6].